ALTSTATION.IO

Pfizer Inc. (PFE) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$27.09

Change

+2.28%

Market Cap

$154.05B

Avg Volume

58.2M

Company Overview

Pfizer Inc. discovers, develops, manufactures, and sells biopharmaceutical products globally, focusing on a broad range of medicines and vaccines. Its offerings span various therapeutic areas, including cardiovascular diseases, infectious diseases, and treatments for conditions like cancer and hemophilia. Key products include the popular blood thinner Eliquis, the COVID-19 vaccine Comirnaty, and antiviral medication Paxlovid. Customers range from wholesalers and retailers to hospitals and government agencies.

Pfizer is a market leader in the pharmaceutical sector, thanks to its extensive portfolio and strong brand recognition. The company’s R&D capabilities give it an edge, especially in addressing unmet medical needs and innovating in areas like mRNA technology. However, competition is fierce with heavyweights like Johnson & Johnson and Merck, and pricing pressures from generic manufacturers pose ongoing threats. Regulatory challenges and the rapid pace of innovation can also impact Pfizer’s market position.

Currently, Pfizer is navigating a post-COVID landscape, focusing on diversifying its product pipeline while managing the revenue decline from pandemic-related sales. The company is actively pursuing strategic collaborations, like its partnership with BioNTech for mRNA developments and investments in biomolecular AI through collaboration with Boltz, PBC. Recent milestones, such as expanding its vaccine portfolio and advancing treatments in immunology and oncology, signal Pfizer’s commitment to growth and innovation despite evolving market dynamics.

Key Financials

Market Cap

$154.05B

Revenue

$62.58B

EBITDA

$25.69B

Gross Margin

75.8%

Profit Margin

12.4%

Revenue Growth

-1.2%

Total Cash

$14.99B

Total Debt

$61.94B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

19.92

Forward P/E

9.51

Beta

0.44

52-Week High

$27.69

52-Week Low

$20.92

EPS

$1.36

50-Day Avg

$25.60

200-Day Avg

$24.70

Price/Book

1.66

Technical Analysis

Over the past 52 weeks, Pfizer Inc. (PFE) has exhibited a predominantly bullish trend, with a price increase culminating at $27.09, reflecting a 12.9% change. Key support is identified around the $24 level, while resistance appears at approximately $30, indicating a well-defined trading range. Notably, the stock has formed a series of higher lows throughout the year, indicating strong upward momentum. In the last few weeks, recent price action has shown a consolidation phase just below the resistance level, suggesting a potential breakout could be imminent. Currently, at $27.09, the price sits comfortably within the 52-week range of approximately $24 to $30, which implies that there is room for growth if the stock successfully breaks through the identified resistance. Overall, the chart suggests continued investor interest and potential for upward movement in the near term.

Recent News and Developments

Here are the latest news and developments for Pfizer Inc

(PFE) stock in the past week:

Market Update

### Pfizer Beats Q4 2025 Earnings and Revenue Estimates, Reaffirms 2026 Guidance

Market Update

Pfizer announced its fourth-quarter 2025 earnings on February 3, 2026, reporting an earnings per share (EPS) of $0.66, which surpassed analysts’ consensus estimates of $0.57. Quarterly revenue also exceeded expectations, reaching $17.56 billion against an estimated $16.93 billion, despite a 1.2% year-over-year decrease. The company also reaffirmed its full-year 2026 revenue guidance in the range o

Market Sentiment and Analyst Recommendations

Bull Case

Pfizer just beat Q4 earnings by 16% on the EPS side ($0.66 vs $0.57 consensus) and revenue by 3.7%, which matters more than the headline -1.2% revenue decline. The obesity drug PF’3944 is moving fast with 10 Phase 3 trials launching in 2026 and a 2028 target, putting Pfizer directly into a market that’s printing money right now. At 19.92x P/E, the stock is trading below its analyst target of $28.71, giving you 6% upside on consensus alone. The TrumpRx program is smart positioning for cost pressure and removes regulatory risk heading into 2026. Cash position of $14.99B against $61.94B debt is manageable, and the company reaffirmed full-year 2026 guidance at $59.5B-$62.5B revenue with $2.80-$3.00 EPS, showing confidence. Chart shows higher lows all year and consolidation near $30 resistance suggests a breakout is plausible.

Bear Case

Revenue is contracting at -1.2% year-over-year, which is the core problem. COVID money dried up, and the company is relying on pipeline assets like PF’3944 that won’t generate material revenue until 2028 at the earliest. The debt load at $61.94B is heavy relative to the $14.99B cash pile, leaving limited room for M&A or shareholder returns if earnings disappoint. Analyst consensus is actually “Hold” not “Buy” despite what the headline says, and BofA already cut its price target citing waning COVID demand. The obesity drug comparison to competitors showed PF’3944 as “slightly inferior,” which is a red flag in a crowded market where efficacy matters. Valuation at 19.92x P/E isn’t cheap for a company with negative growth momentum.

What to Watch

Phase 3 trial enrollment and efficacy data for PF’3944 throughout 2026 will make or break the obesity thesis. Watch Q1 2026 earnings in late April for signs of whether the company can stabilize or grow revenue without COVID tailwinds. The $30 resistance level is critical on the chart; a break above opens $32-$35, but failure to hold $27 could signal weakness back to $24. Monitor the TrumpRx program adoption and whether it pressures margins on the 50-85% discount brands. Track debt reduction progress and free cash flow generation in quarterly reports, especially if obesity drug development accelerates costs. Keep an eye on competitor obesity drug approvals and real-world efficacy comparisons, since the market is consolidating around two or three dominant players. Finally, watch for any changes to analyst consensus; a shift from “Hold” to “Buy” would validate the near-term technical setup.

Analyst Consensus

BUY

Based on 24 analyst opinions

Low Target

$23.00

Mean Target

$28.71

High Target

$35.46

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

N/A

Earnings & Dividends

Next Earnings

Apr 28, 2026

EPS (Trailing)

$1.36

Dividend Yield

649.0%

Payout Ratio

126.5%

Frequently Asked Questions

Is PFE a good stock to buy?

Analysts recommend a BUY on Pfizer Inc. (PFE) with a target price of $28.71, indicating potential upside from the current price of $27.09. The stock’s low forward P/E of 9.51 suggests it may be undervalued compared to its earnings potential.

What is PFE’s price target?

The average analyst target for PFE is $28.71. This target represents about a 6% upside from the current price of $27.09.

Does PFE pay a dividend?

Yes, PFE offers a staggering dividend yield of 649.0%. This high yield makes it attractive for income-seeking investors, especially within the healthcare sector.

What is PFE’s market cap?

Pfizer Inc. has a market capitalization of $154.05 billion. This positions it as one of the major players in the healthcare industry.

What has been the stock’s performance over the last year?

PFE’s stock has traded within a 52-week range of $20.92 to $27.69. Currently, it’s closer to the upper end of its range, reflecting some recovery after earlier volatility.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.